Blocking Wnt5a signaling inhibited NLCs-induced CLL proliferation, migration, and drug resistance, suggesting Wnt5a signaling as a potential therapeutic target in the microenvironment of CLL cells. This evidence concerns the gene WNT5A and B-cell chronic lymphocytic leukemia.